Review

Combined Anti-PD-1/PD-L1 and Anti-angiogenic Therapy: An Emerging Direction for Future NSCLC Treatment

Ming-Tai Li Zhi-Qing Wu Xin Zheng Yan-Hong Zhu Yuxuan Wu Jia-Xin He Xin Wu Jing-Tong Xu Yinyin Qin

Sep 2026 · Current Treatment Options in Oncology · Vol 27 · 0 citations · 114 references

Medicine

TL;DR

Combined therapy has become a pivotal direction in NSCLC systemic treatment and future research should prioritize optimizing treatment regimens, refining real-world safety assessments, and expanding clinical application in patients with complex comorbidities to address current unmet therapeutic needs.

DOI PubMed Semantic Scholar

View source

Similar papers

Review Oct 2026

Beyond PD-L1: emerging clinical and molecular biomarkers of response to immune checkpoint inhibitors in non-small cell lung cancer.

Immune checkpoint inhibitors (ICIs) have radically changed the treatment landscape of non-small cell lung cancer (NSCLC) and significantly improved patients' prognosis in many settings of the disease. Nevertheless, clinical outcomes remain highly heterogeneous, and a substantial proportion of patients do not achieve me...

C. Spagnolo, I. Campo, Elena Fassi et al. · Immunotherapy · 0 citations

Review Sep 2026

Emerging Therapies in Lung Cancer: A Review on Targeted and Immune Based Interventions.

This review encapsulates significant developments in molecularly targeted agents and immune checkpoint inhibitors, emphasising their clinical efficacy, resistance mechanisms, and innovative therapeutic combinations, and reviews pivotal clinical trials and newly filed patents.

K. C. Geervani, R. Maddileti, Kalpi Sania Kausar et al. · Current Drug Discovery Techn... · 0 citations

Open access Aug 2026

Bispecific Antibodies Targeting PD-1/PD-L1 and VEGF in Non-Small Cell Lung Cancer

Mature randomized survival data, longer-term safety assessment, and biomarker development are needed to define optimal patient selection and the clinical role of PD-(L)1/VEGF bispecific antibodies in NSCLC.

Aleena Kuriakose, Salem Gogah, E. Beleva · Journal of Clinical Question... · 0 citations

Open access Sep 2026

Tumor cell-expressed OX40L enhances the efficacy of PD-1 axis blockade in non-small cell lung cancer

Abstract Background Immune checkpoint inhibitors have transformed non-small cell lung cancer (NSCLC) treatment. Understanding the tumor-immune interactions that dictate sensitivity to PD-1 blockade is essential for improving outcomes and optimizing immunotherapy personalization. Methods We performed compartment-specifi...

C. Fernández-Luna, J. Baena, A. Calles et al. · Journal for ImmunoTherapy of... · 0 citations

Open access

Tissue and imaging biomarkers in the treatment of NSCLC

Characteristics of the tumor immune microenvironment and PET imaging of PD-1/PD-L1 have potential as biomarkers for immunotherapy in NSCLC are demonstrated and larger studies are required to validate the predictive value of these approaches.

A. Niemeijer · 0 citations

Review Open access Sep 2026

Targeting pancreatic cancer with natural compounds: molecular mechanisms, preclinical evidence, clinical perspectives, and limitations

This review provides a comprehensive and critical overview of the current evidence regarding selected natural compounds in pancreatic cancer, including apigenin, cannabinoids, curcumin, luteolin, quercetin, resveratrol, vitamin C, and vitamin D, with the aim of supporting the design of future clinical studies and facil...

Alberto Orta, Miguel Ángel Hidalgo-León, C. Lacalle-González et al. · Frontiers in Pharmacology · 0 citations